BiotechTube

ZOSTAVAX®

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Herpes Zoster

Conditions

Herpes Zoster

Trial Timeline

May 14, 2008 → Jun 25, 2008

NCT ID
NCT00681031

About ZOSTAVAX®

ZOSTAVAX® is a approved stage product being developed by Merck for Herpes Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT00681031. Target conditions include Herpes Zoster.

What happened to similar drugs?

4 of 20 similar drugs in Herpes Zoster were approved

Approved (4) Terminated (1) Active (15)
🔄Zoster Vaccine, LiveMerckPhase 3
🔄V212 + PlaceboMerckPhase 3
🔄zoster vaccine live (ZOSTAVAX™) + Comparator: PlaceboMerckPhase 3
🔄ZOSTAVAXMerckPhase 3
🔄Zoster Vaccine, Live (AMP) + Zoster Vaccine, LiveMerckPhase 3
🔄V212 + Matching placeboMerckPhase 3
❌V212 Lot 1 + V212 Lot 2 + V212 Lot 3MerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02960399Pre-clinicalTerminated
NCT00681031ApprovedCompleted

Competing Products

20 competing products in Herpes Zoster

See all competitors
ProductCompanyStageHype Score
mRNA-1608ModernaPhase 2
0
mRNA-1468ModernaPhase 2
0
ASP2151 + Valacyclovir hydrochlorideAstellas PharmaPhase 2
35
ASP2151 + PlaceboAstellas PharmaPhase 1
29
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
35
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
GSK1349572 + EfavirenzShionogiPhase 1
29
Zoster Vaccine, Live + Comparator: PlaceboMerckPhase 2
35
Comparator: V212 + Comparator: PlaceboMerckPhase 1
29
Zoster Vaccine, LiveMerckPhase 3
40
V212 + PlaceboMerckPhase 3
40
zoster vaccine live (ZOSTAVAX™) + Comparator: PlaceboMerckPhase 3
40
ZOSTAVAXMerckPhase 3
40
Zoster Vaccine, Live (AMP) + Zoster Vaccine, LiveMerckPhase 3
40
V212 + PlaceboMerckPhase 2
35
V212 + Matching placeboMerckPhase 3
40
V212 Lot 1 + V212 Lot 2 + V212 Lot 3MerckPhase 3
32
HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%MerckPhase 1
21
V212 + PlaceboMerckPhase 1
29
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ + Comparator: placebo (concomitant-vaccine matched) + Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23MerckPhase 3
40